We categorized the TCGA-BLCA cohort into two groups based on the median expression of TBX3 and discovered that lower TBX3 expression was associated with the basal subtype of BLCA, which is known to be sensitive to immunotherapy and exhibits higher immune cell infiltration 43 (Figure S8A). The gene discussed is TBX3; the disease is bladder transitional cell carcinoma.